- Clovis Oncology (NASDAQ:CLVS) resumed with Neutral rating and $33 (10% upside) price target at Piper Jaffray. Shares up 11% premarket on Rubrace data in mCRPC.
- Immunomedics (NASDAQ:IMMU) initiated with Overweight rating and $33 (45% upside) price target at Piper.
- Quest Diagnostics (NYSE:DGX) resumed with Buy rating and $116 (14% upside) price target at BofA/Merrill Lynch.
- Halozyme (NASDAQ:HALO) resumed with Neutral rating and $17 (flat) price target at Piper.
- LabCorp (NYSE:LH) resumed with Buy rating and $197 (15% upside) price target at BofA/Merrill Lynch.
- Patterson Companies (NASDAQ:PDCO) resumed with Sell rating at Goldman Sachs.
- Henry Schein (NASDAQ:HSIC) resumed with Neutral rating at Goldman.
- Pacific Biosciences of California (NASDAQ:PACB) initiated with Outperform rating and $6.50 (44% upside) price target at Cowen and Company.
- DexCom (NASDAQ:DXCM) upgraded to Neutral with a $125 (6% downside risk) price target at Goldman Sachs.
- Intuitive Surgical (NASDAQ:ISRG) upgraded to Buy with a $610 (17% upside) price target at Canaccord Genuity following Q3 results. Shares up 2% premarket.
- DENTSPLY SIRONA (NASDAQ:XRAY) upgraded to Outperform with a $44 (23% upside) price target at IFS Securities. Upgraded to Buy at Goldman. Shares up 3% premarket.
- Syneos Health (NASDAQ:SYNH) upgraded to Outperform at William Blair.
- Biogen (NASDAQ:BIIB) downgraded to Market Perform at Bernstein. Shares down 1% premarket.
- Rockwell Medical (NASDAQ:RMTI) downgraded to Outperform with an $11 (156% upside) price target at IFS Securities.
- Nevro (NYSE:NVRO) downgraded to Sell at Goldman. Shares down 5% premarket.